Houston health tech startup secures $20M series A, NIH grant amid clinical trials

fresh funding

VenoStent has raised additional funding. Image courtesy of VenoStent

A clinical-stage Houston health tech company with a novel therapeutic device has raised venture capital funding and secured a grant from the National Institutes of Health.

VenoStent Inc., which is currently in clinical trials with its bioabsorbable perivascular wrap, announced the closing of a $20 million series A round co-led by Good Growth Capital and IAG Capital Partners. The two Charleston, South Carolina-based firms also led VenoStent's 2023 series A round that closed last year at $16 million.

Additionally, the company secured a $3.6 million Small Business Innovation Research (SBIR) Phase II Grant from NIH, which will help fund its multi-center, 200-patient, randomized controlled trial in the United States.

Tim Boire, VenoStent CEO and co-founder, describes 2024 so far as "a momentous year" so far for his company.

"In the span of a few months, we initiated our first clinical sites, enrolled the first patients in our large RCT and closed our Series A with Norwest," Boire says in a news release. "We also received the NIH grant, which enables us to execute our trial with the highest degree of quality and rigor to make it as scientifically robust and impactful to patients as possible.

'Each of these are major company milestones that collectively represent many years of intensive and fruitful R&D and collaboration," he continues. "These recent milestones will propel our company forward to an exciting next phase."

Tim Boire is the CEO and co-founder of VenoStent. Photo via LinkedIn

The company's innovation, the SelfWrap, goes around arteriovenous (AV) access sites at the time of AV fistula creation surgery. The device is intended "to accelerate the usability and increase the durability of the fistula sites for chronic kidney disease (CKD) patients requiring hemodialysis," reads the release, "mimicking the arterial environment in veins, which experience a 10x increase in pressure and flow during AV creation and causes the veins to become unusable in dialysis."

Along with the investment, VenoStent announced two new board observers. Norwest General Partner Dr. Zack Scott and Investor Dr. Ehi Akhirome are bringing their expertise to the growing company.

"Norwest's investment is tremendous validation for VenoStent, and we are thrilled to have both Zack and Ehi joining the company's board," VenoStent COO and Co-Founder Geoffrey Lucks adds in the release. "Zack and Ehi have extensive knowledge in our space, and their added value will match the capital and cache of Norwest dollar-for-dollar."

Last year at the same time VenoStent announced its last funding round, the SelfWrap was approved by the U.S. Food and Drug Administration to begin its U.S. Investigational Device Exemption (IDE) study.

"Over half a million people in the U.S. rely on hemodialysis to survive and require an arteriovenous fistula creation surgery in order to receive the treatment. However, the AV fistula procedure has a one-year failure rate of more than 60 percent, which significantly impacts patients' survival rates and quality of life," Scott says in the release. "VenoStent's groundbreaking technology for AV fistula formation, SelfWrap, has the potential to significantly improve these odds. We look forward to working with the VenoStent team as it proves the efficacy of this breakthrough technology in order to improve the lives of hundreds of thousands of CKD patients."

Last summer, Boire told InnovationMap on the Houston Innovators Podcast that he's looking to launch the product in 2026.

From Your Site Articles
Trending Houston startup news from the week included a TMC-based startup raising money. Photo courtesy of TMC

Houston startup trending news includes funding, M&A updates

what's trending

Editor's note: Another week has come and gone, and it's time to round up the top headlines from the past few days. Trending Houston tech and startup news on InnovationMap included an exit for a Houston edtech startup, fresh funding for a med device company, and more.

Houston workforce training startup acquired by California company

Ampersand has been acquired by a college loan and student services provider based in San Diego. Photo ampersandpro.com

A Houston startup, founded to streamline and optimize the intern-company relationship, has been acquired by a student loan and services provider.

San Diego, California-based Ascent, a collegiate student loan company that also provides student support services, announced it has acquired Ampersand, a software platform that provides skills training to young professionals. The news was announced today, July 27, coinciding with National Intern Day.

With the acquisition, Allie Danziger, co-founder and CEO of Ampersand, joins Ascent as senior vice president and general manager of student success. She will lead the company's educational program that focuses on equipping students with skills from education to employment.

“Since launching Ampersand in 2020, we’ve received constant praise from employers, students, and universities on the real education-to-employment skills gap we are filling,” says Danziger in a news release. “I take immense pride in the fact that we’ve helped thousands of students enter the workforce with confidence, earn higher salaries, and get set on the right career path. I know joining the Ascent team will unlock even more opportunities for our combined companies, expanding our collective impact to millions of students and job seekers.” Continue reading.

Houston health tech startup secures $16M series A, prepares for first U.S. clinical trials

A Houston startup based out of the TMC Innovation Factory has announced funding and upcoming trials. Photo courtesy of TMC

Fueled by fresh funding in the bank, a medical device startup has announced upcoming trials.

VenoStent, Inc., a company developing an innovative tool to improve outcomes for hemodialysis patients, has closed $16 million in a series A round of financing. Two Charleston, South Carolina-based firms — Good Growth Capital and IAG Capital Partners — led the round.

The company also announced it received Investigational Device Exemption from the FDA for its United States clinical trial, SAVE-FistulaS.

“Our mission at VenoStent is to improve the quality and length of life of dialysis patients. On the heels of our very promising results in several preclinical studies and a 20-patient feasibility study that led to our Breakthrough Designation last year, this recent IDE approval is perhaps our biggest milestone to date," Tim Boire, CEO of VenoStent, says in a news release. "We now enter an exciting new epoch in our company’s development that we believe will ultimately result in FDA Approval and vastly improve the quality and length of life for patients." Continue reading.

10+ can't-miss Houston business and innovation events for August

Check out these workshops, networking events, conferences, and other goings on in Houston this month. Photo via Getty Images

From networking meetups to startup showcases, August has a smorgasbord of opportunities for Houston innovators.

Here's a roundup of events you won't want to miss out on so mark your calendars and register accordingly. Continue reading.

Houston startup advances in Chevron's unique business accelerator

Currently, methane leak detection requires human evaluation. With this innovative new company's tech, this process can be automated. Photo via Getty Images

A Houston startup that is developing a technology to detect methane leaks has moved on to phase two in Chevron's unique business accelerator.

Aquanta Vision Technologies, a Houston-based climate-tech startup, was selected to participate in the scale-up phase of Chevron Studio, a Houston program that matches entrepreneurs with technologies to turn them into businesses. Aquanta's computer vision software completely automates the identification of methane in optical gas imaging, or OGI. The technology originated from Colorado State University and CSU STRATA Technology Transfer.

Babur Ozden, a tech startup entrepreneur, along with Marcus Martinez, the lead inventor and Dan Zimmerle, co-inventor and director of METEC at CSU Energy Institute, came up with the technology to identify the presence and motion of methane in live video streams. Currently, this process of identifying methane requires a human camera operator to interpret the images. This can often be unreliable in the collection of emissions data. Continue reading.

New Houston investment firm closes $32M fund, announces 3 portfolio companies

A new Houston firm has closed its inaugural fund to invest in health tech. Photo via Getty Images

A new firm has emerged to invest in early-stage tech bio, artificial intelligence, and life sciences.

Modi Ventures announced its inaugural fund, Tech+Bio Fund I, closed at $32 million, an oversubscribed amount. The fund targets companies "shaping the future of humanity," reads a press release from Modi.

“Investing in next generation technologies has always been very lucrative,” says Sahir Ali, general partner of Modi Ventures, in the release. “We are entering an era of software writing software (artificial intelligence), technology that can unravel our individual genetic makeup (gene sequencing), biotech that can reprogram our genes (gene editing), and a fundamental change in how medicine is practiced by leveraging all of the above (precision medicine).

"Tech Bio companies will revolutionize multiple trillion dollar industries, providing early investors with potential for great returns,” he continues. Continue reading.

A Houston startup based out of the TMC Innovation Factory has announced funding and upcoming trials. Photo courtesy of TMC

Houston health tech startup secures $16M series A, prepares for first U.S. clinical trials

money moves

Fueled by fresh funding in the bank, a medical device startup has announced upcoming trials.

VenoStent, Inc., a company developing an innovative tool to improve outcomes for hemodialysis patients, has closed $16 million in a series A round of financing. Two Charleston, South Carolina-based firms — Good Growth Capital and IAG Capital Partners — led the round.

The company also announced it received Investigational Device Exemption from the FDA for its United States clinical trial, SAVE-FistulaS.

“Our mission at VenoStent is to improve the quality and length of life of dialysis patients. On the heels of our very promising results in several preclinical studies and a 20-patient feasibility study that led to our Breakthrough Designation last year, this recent IDE approval is perhaps our biggest milestone to date," Tim Boire, CEO of VenoStent, says in a news release. "We now enter an exciting new epoch in our company’s development that we believe will ultimately result in FDA Approval and vastly improve the quality and length of life for patients."

VenoStent's novel therapeutic medical device is a bioabsorbable wrap. Image courtesy of VenoStent

VenoStent's series A will fund the trial, expand manufacturing capabilities, and more. The company is targeting the more than 800,000 people in the U.S. with end-stage renal disease. Currently, more than half of the surgeries performed to initiate hemodialysis fail within a year. VenoStent's novel therapeutic medical device is a bioabsorbable wrap that reduces vein collapse by providing mechanical support and promoting outward vein growth.

“This trial is designed to provide the highest level of clinical evidence. We’re excited to be in this position to treat the first patients in the United States with this technology, and demonstrate the safety and efficacy of our device,” continues Boire in the release.

Per the release, the company is aiming for FDA Approval and be the first-to-market device to improve hemodialysis access surgery.

“We’re extremely pleased to be partnering with VenoStent on this critical mission. This company and technology are poised for commercial success to address a critical, unmet need,” says Bob Crutchfield, operating partner at Good Growth Capital, in the release.

The TMC Venture Fund also contributed to the series A investment round, along with SNR, Baylor Angel Network / Affinity Fund, Creative Ventures, Cowtown Angels, Alumni Ventures, and other notable angel investors. Past investors in VenoStent include KidneyX, National Science Foundation, National Institute of Health, Y Combinator, Health Wildcatters, and the Texas Halo Fund.

“VenoStent’s data and traction to date is impressive and gives us a lot of confidence in their continued success. We look forward to helping them get this Breakthrough product to market and help patients that are in dire need of this innovative technology,” says Joel Whitley, partner at IAG Capital Partners, in the release.

Tim Boire is the CEO of VenoStent. Photo via LinkedIn

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

TMC launches new biotech partnership with Republic of Korea

international collaboration

Houston's Texas Medical Center has launched its new TMC Republic of Korea BioBridge.

The new partnership brings together the TMC with the Osong Medical Innovation Foundation, or KBIOHealth. The Biobridge aims to support the commercialization of Korean biotech and life science startups in the U.S., foster clinical research, and boost collaboration in the public, private and academic sectors.

Through the partnership, TMC will also develop a Global Innovators Launch Pad to foster U.S. market entry for international health care companies. Founders will be selected to participate in the 10-week program at the TMC Innovation Factory in Houston.

“Gene and cell therapies are driving biotech innovation, opening possibilities for treating diseases once thought untreatable," William McKeon, president and CEO of the Texas Medical Center, said in a news release. "Expanding biomanufacturing capacity is essential to delivering the next wave of these therapies, and partnerships with leading innovators will strengthen our efforts in Houston and internationally.”

McKeon officially signed the TMC Korea BioBridge Memorandum of Understanding with Myoung Su Lee, chairman of KBIOHealth, in South Korea in October.

"This collaboration marks a significant milestone for Korea’s biohealth ecosystem, creating a powerful bridge between Osong and Houston," Lee added in the release. "By combining KBIOHealth’s strength in research infrastructure and Korea’s biotech talent with TMC’s global network and accelerator platform, we aim to accelerate innovation and bring transformative solutions to patients worldwide.”

This is the seventh international strategic partnership for the TMC. It launched its first BioBridge with the Health Informatics Society of Australia in 2016. It launched its TMC Japan BioBridge, focused on advancing cancer treatments, last year. It also has BioBridge partnerships with the Netherlands, Ireland, Denmark and the United Kingdom.

Houston startup surge, job forecast, and more trending news to know

Trending News

Editor's note: 2026 is here, and we are heading into the new year with a surge in local startup activity and job growth in the local health care sector. As we look ahead to 2026, here are five trending news stories from InnovationMap, published at the close of the year:


1. New report shows surge in startup activity in Houston and across Texas

Photo by Rome Wilkerson on Unsplash

Houston and the rest of Texas are experiencing a boom in the creation of startups. One barometer of growth in startup activity: The Houston metro area saw a 92 percent rise from 2024 to 2025 in the number of account applications submitted to Bluevine, a banking platform for small businesses. Continue reading.

2. Houston poised to add 30,900 new jobs in 2026, forecast says

The health care sector will lead Houston job growth in 2026. Photo via Houston Methodist

Buoyed by the growing health care sector, the Houston metro area will add 30,900 jobs in 2026, according to a new forecast from the Greater Houston Partnership. The report predicts the Houston area’s health care sector will tack on 14,000 jobs in 2026, which would make it the No. 1 industry for local job growth. Continue reading.

3. UH receives $2.6M gift to support opioid addiction research and treatment

UH has received a new financial gift towards the Michael C. Gibson Addiction Research Program, which is developing a fentanyl vaccine. Photo via Unsplash.

The estate of Dr. William A. Gibson has granted the University of Houston a $2.6 million gift to support and expand its opioid addiction research, including the development of a fentanyl vaccine that could block the drug's ability to enter the brain. Continue reading.

4. These 50+ Houston scientists rank among world’s most cited

UH Professor Zhifeng Ren is one of 50 Houston-area researchers named to Clarivate’s Highly Cited Researchers list for their broad and lasting impact. Photo courtesy UH.

Fifty-one scientists and professors from Houston-area universities and institutions were named among the most cited in the world for their research in medicine, materials sciences and an array of other fields. The Clarivate Highly Cited Researchers considers researchers who have authored multiple "Highly Cited Papers" that rank in the top 1percent by citations for their fields in the Web of Science Core Collection. The final list is then determined by other quantitative and qualitative measures by Clarivate's judges to recognize "researchers whose exceptional and community-wide contributions shape the future of science, technology and academia globally." Continue reading.

5. 6 Houstonians named to prestigious national group of inventors

Vineet Gupta, Eva Harth, Dr. Raghu Kalluri, Todd Rosengart, Sanjoy Paul and Dr. Jochen Reiser have been named to the National Academy of Inventors' 2025 class of fellows. Photos via the institutions.

Six Houston scientists and innovation leaders have been named to the National Academy of Inventors’ newest class of fellows. The award is the highest professional distinction awarded to academic inventors by the NAI. The 2025 class is made up of 169 fellows who hold more than 5,300 U.S. patents, according to the organization. The group hails from 127 institutions across 40 U.S. states. The Houston-based inventors are leading fields from AI to chemistry to cancer research. Continue reading.

Here are the 10 most-read Houston innovation headlines of 2025

Year in Review

Editor's note: As we ring in the new year, we're looking back at the stories that defined Houston innovation in 2025. The 10 most-read InnovationMap stories of the year highlight diversity, mentorship, and the startups that are shaping the future.

Houston named No. 2 most diverse major U.S. city for 2025

Houston is the No. 2 most diverse large city and the No. 5 most diverse city overall in America. Sky Noir Photography by Bill Dickinson/Getty Images

Houston has always been a diverse place, embracing people of many different cultural and socioeconomic backgrounds. The city earned recognition in WalletHub's rankings of the most diverse large American cities for 2025. The 2025 edition was the final installment in WalletHub's diversity study series, which annually compared 501 U.S. cities across 13 metrics in five categories that encompass "diversity" across socioeconomic, cultural, economic, household, and religious factors. Houston nearly topped the list of large U.S. cities, coming in at No. 2, and it ranked No. 5 in the overall national comparison.

What to know about the new emission inspection to register your car in Texas

An inspection is no longer required to renew registration, but an emission evaluation is. Photo by Tim Leviston/Getty Images

As of January 1, 2025, Texas vehicle owners no longer needed to obtain a safety inspection prior to vehicle registration. House Bill 3297, which passed during the 88th Legislature in 2023, eliminated the safety inspection program for non-commercial vehicles. But under the new law, the $7.50 fee that drivers had to pay as a safety inspection fee has not gone away. It now appears on your registration notice under a new name: "Inspection Program Replacement Fee."

Houston humanoid robotics startup secures millions in pre-seed funding

A concept design rendering of Persona AI's humanoid robot. Co-founder and CEO Nic Radford expects customers to take delivery of its first robot in 18 to 24 months. Rendering courtesy Persona AI.

In February 2025, a Houston-based startup developing AI-powered humanoid robots for manufacturers and other businesses raised more than $10 million in pre-seed funding — less than a year after its founding. Nic Radford, co-founder and CEO of Persona AI, declined to disclose the amount raised, however, he told InnovationMap that it was an eight-figure total.

2 Houston universities declared among world’s best in 2026 rankings

Rice is the No. 2 best school in Texas, and No. 119 in the world. Photo via Rice University

Two Houston universities were in a class of their own, earning top spots on a global ranking of the world's best universities. Rice University and University of Houston were among the top 1,200 schools included in the QS World University Rankings 2026. Ten more schools across Texas made the list.

Announcing the 2025 Houston Innovation Awards finalists

Meet the finalists for the Houston Innovation Awards, taking place Nov. 13. Graphic via Gow Media

In October 2025, InnovationMap was proud to reveal the finalists for the fifth-annual Houston Innovation Awards. This year's finalists were determined by an esteemed panel of judges, comprised of past award winners and InnovationMap editorial leadership, and they represented the best of Houston innovation this year.

Meet 6 mentors who are helping the Houston startup scene flourish

The 2025 Mentor of the Year will be announced on Nov. 13. Courtesy photos

Few founders launch successful startups alone — experienced and insightful mentors often play an integral role in helping business and founders thrive. The Houston startup community is home to many mentors who are willing to lend an ear and share advice to help entrepreneurs meet their goals. The Mentor of the Year category in our 2025 Houston Innovation Awards honored an individual like this, who dedicates their time and expertise to guide and support budding entrepreneurs. The award was presented by Houston City College Northwest.

Houston Nobel Prize nominee earns latest award for public health research

Dr. Peter Hotez with Dr. Maria Elena Bottazzi. Photo courtesy of TMC

Houston vaccine scientist Dr. Peter Hotez added one more prize to his shelf. Hotez — dean of the National School of Tropical Medicine and professor of Pediatrics and Molecular Virology & Microbiology at Baylor College of Medicine, co-director of the Texas Children’s Center for Vaccine Development (CVD) and Texas Children’s Hospital Endowed Chair of Tropical Pediatrics — is no stranger to impressive laurels. In 2022, he was even nominated for a Nobel Peace Prize for his low-cost COVID vaccine. His big win of 2025 was this year’s Hill Prize, awarded by the Texas Academy of Medicine, Engineering, Science and Technology (TAMEST).

Apple announces 250,000-square-foot Houston factory as part of $500B plan

Apple's Houston factory will open in 2026. Getty Images

As part of a more than $500 billion, four-year investment across the U.S., Silicon Valley tech giant Apple announced plans to build a factory in Houston that will produce servers for its data centers to support the company’s artificial intelligence (AI) business. In a February 24 announcement, Apple said the company and its partners will build the 250,000-square-foot factory. The plant, set to open in 2026, will employ thousands of people.

10 Houston billionaires make Forbes' list of richest Americans in 2025

Pictured: Nancy and Richard Kinder, the richest Houstonian, according to the Forbes 400. Photo by Michelle Watson/Catchlight Group

America's wealthiest billionaires were $1.2 trillion richer in 2025, bringing their collective worth to a staggering $6.6 trillion. And Houston's own Richard Kinder became the richest billionaire in the city, according to the annual Forbes 400. The Kinder Morgan chairman was named the 11th richest Texas resident and ranked as the 108th richest American. He dethroned Tilman Fertitta to claim the title as the wealthiest Houstonian.

2 Houston suburbs named among 10 best places to live by U.S. News & World Report

Pearland is the No. 2 best place to live in the U.S. Photo via pearlandedc.com

The Houston suburbs of Pearland and League City landed among the top 10 best places to live in 2025, according to U.S. News & World Report. For the 2025-2026 "Best Places to Live in the U.S." rankings, U.S. News expanded its coverage from 150 to 250 U.S. cities, and updated its methodology to examine each city based on five livability indexes: Quality of life, value, desirability, job market, and net migration. Pearland ranked No. 3 nationwide, earning a 7.0 score alongside No. 1-winning Johns Creek, Georgia and No. 2 winner Carmel, Indiana.

View All Listings